The global market for smart inhalers is projected to experience significant growth, reaching USD 6.86 billion by 2035, driven largely by advancements in AI technology and increasing adoption of connected devices in respiratory care.
According to a recent market research report, the smart inhalers market was valued at USD 1.85 billion in 2025, with an anticipated compound annual growth rate (CAGR) of 14.0% from 2026 to 2035. This growth is attributed to a rise in the prevalence of asthma and chronic obstructive pulmonary disease (COPD), alongside the growing integration of AI-enabled connected inhalers and digital health platforms that facilitate remote patient monitoring and medication adherence.
Smart inhalers utilize Bluetooth technology and mobile health applications to enhance medication adherence. They automatically track inhalation events and remind users of missed doses, allowing healthcare providers to monitor patient compliance in real time. This technological integration addresses the issue of poor medication adherence, which affects nearly half of asthma patients, thereby reducing the risk of exacerbations and hospitalizations.
North America currently dominates the market, accounting for a substantial share due to its advanced healthcare infrastructure and high incidence of respiratory diseases. The United States alone is expected to grow from approximately USD 0.78 billion in 2025 to USD 2.84 billion by 2035. Meanwhile, Europe is also expanding its investments in digital respiratory healthcare, driven by stringent regulations and a robust healthcare system.
The rise of smart inhalers signifies a crucial shift towards more personalized and efficient management of respiratory diseases. As technology continues to evolve, the integration of AI and digital health solutions is likely to play a pivotal role in enhancing patient outcomes and optimizing healthcare delivery in the respiratory sector.